Genaissance Pharmaceuticals to Present at CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference

Genaissance Pharmaceuticals to Present at CIBC World Markets
Annual Biotechnology and Specialty Pharmaceuticals Conference 


NEW HAVEN, Conn., March 31  /PRNewswire-FirstCall/ -- Genaissance
Pharmaceuticals, Inc. (NASDAQ:GNSC) today announced that Kevin Rakin, President
and Chief Executive Officer of Genaissance, will present at the CIBC World
Markets Annual Biotechnology & Specialty Pharmaceuticals Conference in New York
at 11:30 a.m. Eastern time on Monday, April 4, 2005.

Mr. Rakin's remarks will also be available live via an audio webcast that can
be accessed through the Company's website at: http://www.genaissance.com/ .

Genaissance Pharmaceuticals, Inc. is developing innovative products based on
its proprietary pharmacogenomic technology and has a revenue-generating
business in DNA and pharmacogenomic products and services.  Genaissance also
markets its proprietary FAMILION(TM) Test, designed to detect mutations
responsible for causing Familial Long QT and Brugada Syndromes, two causes of
sudden cardiac death.  The Company's product development strategy is focused on
drug candidates with promising clinical profiles and finding genetic markers to
identify a responsive patient population.  This strategy is designed to enable
Genaissance to leverage existing clinical data and, thus, reduce the costs and
risks associated with traditional drug development and increase the probability
of clinical success and commercialization.  The Company's lead therapeutic
product, vilazodone for depression, is in Phase II of development.  For more
information on Genaissance, visit the Company's website at:
http://www.genaissance.com/ . 

DATASOURCE: Genaissance Pharmaceuticals, Inc.



CONTACT: Kevin Rakin, President & Chief Executive Officer of Genaissance

Pharmaceuticals, Inc., [phone]; or Rhonda Chiger (investors)

Rx Communications Group, [phone]; Tom Redington (media) of Redington,

Inc., [phone], both for Genaissance Pharmaceuticals, Inc.



Web site:  http://www.genaissance.com/ 

Copyright